Related Experiment Video
Updated: May 3, 2026
04:40
Author Spotlight: Advancing Cancer Associated Thrombosis Research in Rodent Models
Published on: January 5, 2024
3.2K
Antiangiogenic therapy inhibits venous thrombus resolution
Colin E Evans1, Steven P Grover, Julia Humphries
1From the Academic Department of Vascular Surgery, Cardiovascular Division, Kings College London, BHF Centre of Research Excellence & NIHR Biomedical Research Centre at Kings Health Partners, St Thomas' Hospital, London, United Kingdom.
Arteriosclerosis, Thrombosis, and Vascular Biology
|January 18, 2014
Summary
Antiangiogenic therapy hinders venous thrombus resolution, potentially prolonging obstruction and increasing risks in cancer patients. This finding impacts treatment considerations for venous thromboembolism complications.
Area of Science:
- Vascular Biology
- Oncology
- Thrombosis Research
Background:
- Venous thromboembolism (VTE) is a serious complication in cancer patients.
- Antiangiogenic agents may increase VTE incidence.
- Thrombus resolution involves complex remodeling processes.
Purpose of the Study:
- To investigate the effect of antiangiogenic therapy on venous thrombus resolution.
- To determine if inhibiting angiogenesis impacts the natural process of thrombus breakdown.
Main Methods:
- Venous thrombi were induced in mouse models.
- Mice were treated with axitinib or 2-methoxyestradiol (2ME), both antiangiogenic agents, or vehicle control.
- Thrombus size, recanalization, neovascularization, and inflammatory cell content were assessed.
Main Results:
- Axitinib and 2ME significantly inhibited thrombus resolution and vein recanalization compared to controls.
- Both agents reduced thrombus neovascularization and collagen content.
- Macrophage accumulation was reduced by axitinib and 2ME; neutrophils were reduced by 2ME only.
Conclusions:
- Antiangiogenic therapy demonstrably inhibits venous thrombus resolution.
- This inhibition may lead to persistent venous obstruction and potential thrombus extension.
- Clinical management of VTE in cancer patients on antiangiogenic therapy requires careful consideration.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
482
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
482
01:30Venous Thrombosis I: Introduction
822
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
822
01:30Venous Thrombosis IV: Nursing Management
415
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
415
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.7K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.7K
01:20Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
469
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
469
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.6K